Rankings
▼
Calendar
VRDN (Viridian Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
VRDN
Viridian Therapeutics, Inc.
Mkt Cap
$3B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$71M
Net Income (TTM)
-$343M
EPS (TTM)
-$3.32
Free Cash Flow (TTM)
-$277M
Gross Margin
99.5%
Op. Margin
-512.9%
Net Margin
-483.6%
FCF Margin
-390.8%
P/S Ratio (TTM)
35.6x
P/E Ratio (TTM)
—
YoY Rev Growth
+23359.9%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$98K
$98K
-$72M
Q2 23
$72K
$72K
-$59M
Q3 23
$72K
$72K
-$51M
Q4 23
$72K
$72K
-$71M
Q1 24
$72K
$72K
-$56M
Q2 24
$72K
$72K
-$72M
Q3 24
$86K
$86K
-$83M
Q4 24
$72K
$72K
-$87M
Q1 25
$72K
$72K
-$94M
Q2 25
$75K
$75K
-$107M
Q3 25
$71M
$71M
-$40M
Q4 25
$132K
-$188K
-$123M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
1526.2x
—
Q2 23
1717.2x
—
Q3 23
7274.5x
—
Q4 23
8039.0x
—
Q1 24
8764.8x
—
Q2 24
8764.8x
—
Q3 24
8358.5x
—
Q4 24
8358.5x
—
Q1 25
8358.5x
—
Q2 25
8276.3x
—
Q3 25
35.7x
—
Q4 25
35.6x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$62M
-$62M
Q2 23
-$45M
-$46M
Q3 23
-$39M
-$39M
Q4 23
-$38M
-$38M
Q1 24
-$45M
-$45M
Q2 24
-$46M
-$46M
Q3 24
-$68M
-$68M
Q4 24
-$73M
-$73M
Q1 25
-$93M
-$93M
Q2 25
-$75M
-$75M
Q3 25
-$85M
-$85M
Q4 25
-$24M
-$24M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$115K
Q2 23
$331K
Q3 23
$404K
Q4 23
$48K
Q1 24
$0
Q2 24
$104K
Q3 24
$293K
Q4 24
$114K
Q1 25
$86K
Q2 25
$42K
Q3 25
$127K
Q4 25
$240K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-54.6%
+178.0%
Q2 23
-71.9%
+99.0%
Q3 23
-94.0%
+65.6%
Q4 23
-31.4%
+45.5%
Q1 24
-26.5%
-22.9%
Q2 24
+0.0%
+21.8%
Q3 24
+19.4%
+62.9%
Q4 24
+0.0%
+22.4%
Q1 25
+0.0%
+67.8%
Q2 25
+4.2%
+47.9%
Q3 25
+81958.1%
+32.3%
Q4 25
+83.3%
+40.4%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$15M
15526.5%
Q2 23
$12M
17086.1%
Q3 23
$14M
18897.2%
Q4 23
$26M
36177.8%
Q1 24
$13M
17622.2%
Q2 24
$12M
16343.1%
Q3 24
$9M
10139.5%
Q4 24
$9M
12465.3%
Q1 25
$10M
14194.4%
Q2 25
$11M
14458.7%
Q3 25
$11M
15.9%
Q4 25
$12M
9082.6%
marketcaparena.com
OpEx Breakdown
R&D
G&A
Quarter
R&D
G&A
Q1 23
$51M
$22M
Q2 23
$40M
$19M
Q3 23
$30M
$21M
Q4 23
$39M
$33M
Q1 24
$41M
$15M
Q2 24
$56M
$16M
Q3 24
$69M
$14M
Q4 24
$72M
$16M
Q1 25
$77M
$17M
Q2 25
$87M
$20M
Q3 25
$86M
$24M
Q4 25
$89M
$34M
marketcaparena.com
Revenue Segments
Collaboration Revenue
Collaboration
License
Quarter
Collaboration Revenue
Collaboration
License
Q1 23
$100K
—
—
Q3 25
—
$570K
$70M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$89M
$285M
$374M
Q2 23
$87M
$247M
$334M
Q3 23
$112M
$201M
$313M
Q4 23
$103M
$375M
$477M
Q1 24
$92M
$522M
$613M
Q2 24
$108M
$464M
$571M
Q3 24
$200M
$553M
$753M
Q4 24
$100M
$618M
$718M
Q1 25
$116M
$520M
$637M
Q2 25
$117M
$446M
$563M
Q3 25
$170M
$321M
$491M
Q4 25
$212M
$662M
$875M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
42M
+4.2%
Q2 23
43M
+2.4%
Q3 23
44M
+0.9%
Q4 23
50M
+13.8%
Q1 24
61M
+23.0%
Q2 24
64M
+4.5%
Q3 24
66M
+4.0%
Q4 24
80M
+20.5%
Q1 25
81M
+1.6%
Q2 25
82M
+0.3%
Q3 25
82M
+0.2%
Q4 25
85M
+3.7%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$154K
28
FY 15
$79K
32
FY 16
$74K
45
FY 17
$62K
65
FY 18
$105K
80
FY 19
$97K
46
FY 20
$39K
27
FY 21
$59K
50
FY 22
$21K
86
FY 23
$3K
94
FY 24
$2K
143
FY 25
$281K
252
marketcaparena.com